A New Drug Against Severe Malaria – Part 2 of 3
The study authors, Nicholas White of Mahidol University in Bangkok, Thailand, and colleagues from the AQUAMAT lessons group, also noted that while artesunate is more expensive to buy, quinine is more expensive to administer. “A major factor restricting the deployment of artesunate has been unavailability of a artifact satisfying international good manufacturing standards. The most widely used product, assessed in this study, does not yet have this certification, which has prevented deployment in some countries. This barrier must be defeated speedily so that parenteral artesunate can be deployed in malaria-endemic areas to save lives,” White’s team wrote in a news release.
The study, which was released online in advance of publication in an upcoming rotogravure issue of The Lancet, was scheduled for presentation Saturday at a meeting of the American Society for Tropical Medicine and Hygiene, held in Atlanta. A previous study found that the malaria death rate to each Southeast Asian adults treated with artesunate was 14 percent, compared with 23 percent for those treated with quinine. Following that study, the World Health Organization changed its guidelines to support artesunate for severe malaria in adults.